Clinical Trial Update: Regorafenib Assessment in Refractory Advanced Colorectal Cancer(RegARd-C) [Phase 2]

View source ↗

Summary

Phase 2 trial update for regorafenib in refractory advanced colorectal cancer (RegARd-C) completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Regorafenib (regorafenib)

Snippet

Sponsor: Jules Bordet Institute | Conditions: Advanced Chemorefractory Colorectal Adenocarcinoma | Phase 2 | Status: COMPLETED